Article

Novel RNA Polymerase I and Cyclin Dependent Kinase combination therapy for the treatment of aggressive Acute Myeloid Leukemia

2025-07-21

Abstract excerpt

Despite advances in therapy, specific subtypes Acute Myeloid Leukaemia (AML) remains largely incurable. The first-in-class RNA Polymerase I (Pol I) inhibitor, CX-5461, has demonstrated promising activity in both haematological malignancies and solid tumours by selectively inhibiting ribosome biogenesis to induce nucleolar stress, a critical vulnerability in rapidly proliferating cancer cells. CX-5461 has undergone...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: aa2219ff-c29b-53d2-9a90-52ceff891edd
DOI: 10.1101/2025.07.21.664618

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Novel RNA Polymerase I and Cyclin Dependent Kinase combination therapy for the treatment of aggressive Acute Myeloid LeukemiaDOI 10.1101/2025.07.21.664618Read

The novel RNA polymerase I transcription inhibitor PMR-116 exploits a critical therapeutic vulnerability in a broad-spectrum of high <i>MYC</i> malignanciesSemantic proximity Read

Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell populationSemantic proximity Read

TP53-agnostic lethality through combined pan-HDAC and CDK inhibition in acute myeloid leukemia.Semantic proximity Read

Integrated Multi-Omics and Interactome Analysis of CDK8 Inhibition Reveals Erythroid Differentiation Programs and BET Synergy in AML Stem-like CellsSemantic proximity Read

Combination Strategies with Menin Inhibitors for Acute LeukemiaSemantic proximity Read

Proteomic profiling reveals pleiotropic antimetabolite activity of triciribine in acute lymphoblastic leukemiaSemantic proximity Read

Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemiaSemantic proximity Read

A novel Cdk9 inhibitor preferentially targets tumor cells and synergizes with fludarabineSemantic proximity Read

PI3K/mTOR activity sensitizes cancer cells to nucleolar stressSemantic proximity Read

Addressing Transcriptional Dysregulation in Cancer through CDK9 InhibitionSemantic proximity Read

Shifting Beyond Classical Drug Synergy in Combinatorial Therapy through Solubility AlterationsSemantic proximity Read

Silencing Of The DNA Damage Repair Regulator PPP1R15A Sensitizes Acute Myeloid Leukemia Cells To ChemotherapySemantic proximity Read